Publications by authors named "Guru Sonpavde"

100Publications

Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.

Expert Rev Anticancer Ther 2020 Nov 28. Epub 2020 Nov 28.

Dana Farber Cancer Institute , Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2021.1855981DOI Listing
November 2020

p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma.

Arch Pathol Lab Med 2020 Nov 25. Epub 2020 Nov 25.

From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Acosta, Barletta, Schnitt, Hirsch).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2020-0262-OADOI Listing
November 2020

Considerations in prescribing pharmacotherapy for localized and metastatic urothelial carcinoma.

Expert Opin Pharmacother 2020 Aug 31:1-4. Epub 2020 Aug 31.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute , Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2020.1813717DOI Listing
August 2020

Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?

Urology 2020 Aug 14. Epub 2020 Aug 14.

Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2020.08.004DOI Listing
August 2020

Neoadjuvant therapy for muscle-invasive bladder cancer.

Expert Rev Anticancer Ther 2020 Jul 30;20(7):603-614. Epub 2020 Jun 30.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute , Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1784011DOI Listing
July 2020

Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.

Cancer Immunol Immunother 2020 Nov 6;69(11):2305-2317. Epub 2020 Jun 6.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, CA, 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-020-02609-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572640PMC
November 2020

Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.

Clin Genitourin Cancer 2020 Mar 31. Epub 2020 Mar 31.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.03.013DOI Listing
March 2020

Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival.

Radiology 2020 Jun 31;295(3):572-580. Epub 2020 Mar 31.

From the Department of Imaging (F.A., K.W., R.G., A.B.S.) and Lank Center for Genitourinary Oncology (A.H.N., G.S.), Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215; and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (F.A., K.W., R.G., S.G.S., A.B.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2020191770DOI Listing
June 2020

Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature.

Clin Genitourin Cancer 2020 06 5;18(3):e266-e276. Epub 2019 Dec 5.

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272305PMC
June 2020

Reply by Authors.

J Urol 2020 06 16;203(6):1155. Epub 2020 Mar 16.

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000746.03DOI Listing
June 2020

A CD24-p53 axis contributes to African American prostate cancer disparities.

Prostate 2020 05 13;80(8):609-618. Epub 2020 Mar 13.

Department of Genetics and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23973DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176538PMC
May 2020

PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.

Clin Genitourin Cancer 2020 06 16;18(3):e254-e259. Epub 2019 Oct 16.

PUCRS School of Medicine, Porto Alegre, Brazil; Dana Farber Cancer Institute/Harvard Medical School, Boston, MA; Department of Medical Oncology, Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.10.014DOI Listing
June 2020

Capturing recurrence in urothelial carcinoma: "more than meets the eye".

Transl Androl Urol 2019 Dec;8(Suppl 5):S524-S527

Department of Medicine, Division of Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2019.12.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989855PMC
December 2019

The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.

Cancer Treat Res Commun 2020 Jan 7;23:100165. Epub 2020 Jan 7.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA 02215, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100165DOI Listing
January 2020

PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression.

Matrix Biol 2020 07 23;89:43-58. Epub 2020 Jan 23.

Department of Urology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA; Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35233, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35233, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.matbio.2020.01.001DOI Listing
July 2020

Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials.

Oncol Rev 2019 Jul 25;13(2):455. Epub 2019 Nov 25.

Division of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/oncol.2019.455DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886005PMC
July 2019

Erdafitinib in Urothelial Carcinoma.

N Engl J Med 2019 10;381(16):1594

Lund University, Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1911187DOI Listing
October 2019

Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy.

Urology 2020 Jan 3;135:44-49. Epub 2019 Oct 3.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2019.09.029DOI Listing
January 2020

Investigational MET inhibitors to treat Renal cell carcinoma.

Expert Opin Investig Drugs 2019 Oct 3;28(10):851-860. Epub 2019 Oct 3.

Huntsman Cancer Institute, University of Utah , Salt Lake City , UT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1673366DOI Listing
October 2019

Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.

Expert Opin Investig Drugs 2019 Oct 17;28(10):821-826. Epub 2019 Sep 17.

Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543784.2019.1
Publisher Site
http://dx.doi.org/10.1080/13543784.2019.1667332DOI Listing
October 2019

Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.

Eur Urol Oncol 2020 10 9;3(5):680-686. Epub 2019 Mar 9.

Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.02.002DOI Listing
October 2020

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.

Eur Urol Oncol 2020 08 30;3(4):540-543. Epub 2018 Nov 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.11.006DOI Listing
August 2020

Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer.

Transl Oncol 2019 Nov 8;12(11):1416-1424. Epub 2019 Aug 8.

Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2019.07.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700437PMC
November 2019

A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer.

Transl Androl Urol 2019 Jul;8(Suppl 3):S254-S256

Genitourinary Oncology Division, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2018.12.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642977PMC
July 2019

Advanced urothelial cancer: a radiology update.

Abdom Radiol (NY) 2019 12;44(12):3858-3873

Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-02148-3DOI Listing
December 2019

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Eur Urol Oncol 2018 08 30;1(3):190-198. Epub 2018 May 30.

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.05.002DOI Listing
August 2018

Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:284-300. Epub 2019 May 17.

4 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_237449DOI Listing
January 2019

Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Cancer Lett 2019 07 8;454:1-13. Epub 2019 Apr 8.

Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, 30310, USA; Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA, 30310, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835193021
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2019.04.001DOI Listing
July 2019

Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy.

Eur Urol Focus 2020 01 23;6(1):14-16. Epub 2019 Mar 23.

Genitourinary Oncology Division, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.03.011DOI Listing
January 2020

Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Curr Treat Options Oncol 2019 02 11;20(2):12. Epub 2019 Feb 11.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0609-6
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0609-6DOI Listing
February 2019

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?

Cancer 2019 04 11;125(8):1319-1329. Epub 2019 Jan 11.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31926
Publisher Site
http://dx.doi.org/10.1002/cncr.31926DOI Listing
April 2019

Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.

World J Urol 2019 Oct 16;37(10):2059-2065. Epub 2018 Nov 16.

Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00345-018-2550-x
Publisher Site
http://dx.doi.org/10.1007/s00345-018-2550-xDOI Listing
October 2019

Systemic treatments for metastatic urothelial carcinoma.

Expert Opin Pharmacother 2019 02 9;20(2):201-208. Epub 2018 Nov 9.

b Lank Center for Genitourinary Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1544242DOI Listing
February 2019

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

J Clin Oncol 2018 Oct 19:JCO1800328. Epub 2018 Oct 19.

Thomas P. Slavin, Kar Wing Kevin Tsang, Susan L. Neuhausen, Stacy W. Gray, and Jeffrey N. Weitzel, City of Hope, Duarte; Kimberly C. Banks, Darya Chudova, Justin I. Odegaard, Rebecca J. Nagy, Christine E. Lee, and Richard B. Lanman, Guardant Health, Redwood City; Razelle Kurzrock, University of California, San Diego, Moores Cancer Center, San Diego, CA; Geoffrey R. Oxnard, Dana-Farber Cancer Institute; Aditya Bardia, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Massimo Cristofanilli, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Angel A. Rodriguez, Houston Methodist Hospital; Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mike F. Janicek, Arizona Oncology Associates Gynecology Oncology, Scottsdale, AZ; Michael Lilly, Medical University of South Carolina, Charleston, SC; and Guru Sonpavde, The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00328
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286162PMC
October 2018

Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?

J Clin Oncol 2018 Nov 13;36(32):3189-3191. Epub 2018 Sep 13.

Matthew Mossanen, Brigham and Women's Hospital, Harvard Medical School, Center for Surgery and Public Health, Brigham and Women's Hospital; and Dana-Farber Cancer Institute, Boston, MA; Joshua Caldwell, Harvard Medical School, Boston, MA; Guru Sonpavde, Dana-Farber Cancer Institute, Boston, MA; and Lisa Soleymani Lehmann, National Center for Ethics in Health Care, Veterans Health Administration, Washington, DC, and Harvard Medical School and Harvard T.H. Chan School of Public Health, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00577DOI Listing
November 2018

Immunotherapy for advanced penile cancer - rationale and potential.

Nat Rev Urol 2018 Dec;15(12):721-723

Genitourinary Oncology Division, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-018-0083-0DOI Listing
December 2018

A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.

Neoplasia 2018 09 15;20(9):894-904. Epub 2018 Aug 15.

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA; Informatics Institute, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14765586183018
Publisher Site
http://dx.doi.org/10.1016/j.neo.2018.07.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098199PMC
September 2018

Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.

World J Urol 2018 Nov 14;36(11):1767-1774. Epub 2018 Jun 14.

Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-2371-yDOI Listing
November 2018

Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

Prostate Cancer Prostatic Dis 2018 09 1;21(3):419-430. Epub 2018 Jun 1.

Department of Medicine, School of Medicine, Duke University, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0049-6
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0049-6DOI Listing
September 2018

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Eur Urol 2019 01 16;75(1):88-99. Epub 2018 Apr 16.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.028DOI Listing
January 2019

Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?

Eur Urol 2018 07 10;74(1):63-65. Epub 2018 Apr 10.

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.015DOI Listing
July 2018

Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.

Urol Clin North Am 2018 May;45(2):143-154

Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis Street, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2017.12.001DOI Listing
May 2018

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.

Asian J Androl 2018 May-Jun;20(3):230-237

Dana Farber Cancer Institute, Genitourinary Oncology Section, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://www.ajandrology.com/text.asp?2018/20/3/230/227854
Publisher Site
http://dx.doi.org/10.4103/aja.aja_1_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952476PMC
June 2019

The effect of treatment at minority-serving hospitals on outcomes for bladder cancer.

Urol Oncol 2018 05 15;36(5):238.e7-238.e17. Epub 2018 Feb 15.

Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439183001
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2018.01.010DOI Listing
May 2018

Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.

BJU Int 2018 06 6;121(6):871-879. Epub 2018 Mar 6.

Sanofi, Bridgewater, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14152DOI Listing
June 2018

Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies.

Clin Genitourin Cancer 2018 04 27;16(2):e277-e287. Epub 2017 Dec 27.

Dana Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.12.006DOI Listing
April 2018

Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma.

Curr Treat Options Oncol 2018 01 18;19(1). Epub 2018 Jan 18.

Department of Medical Oncology, Genitourinary Oncology Section, Dana-Farber Cancer Institute, 450 Brookline Avenue, D1230F, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0522-4DOI Listing
January 2018

The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.

Expert Opin Investig Drugs 2018 02 24;27(2):163-170. Epub 2018 Jan 24.

b Department of Medicine, Division of Hematology and Oncology , University of Alabama at Birmingham Comprehensive Cancer Center , Birmingham , AL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2018.1427731DOI Listing
February 2018

Taxane-based Combination Therapies for Metastatic Prostate Cancer.

Eur Urol Focus 2019 05 21;5(3):369-380. Epub 2017 Dec 21.

Genitourinary Oncology Section, Dana Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2017.11.009DOI Listing
May 2019

Promising immunotherapy for prostate cancer.

Expert Opin Biol Ther 2018 02 12;18(2):109-120. Epub 2017 Dec 12.

b Department of Medical Oncology, GU section , Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1406916DOI Listing
February 2018

Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.

Expert Opin Emerg Drugs 2017 12 19;22(4):347-355. Epub 2017 Dec 19.

b Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2017.1416092DOI Listing
December 2017

JAVELIN: avelumab another spear to fight urothelial carcinoma.

Lancet Oncol 2018 01 5;19(1):5-7. Epub 2017 Dec 5.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045173090
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(17)30901-4DOI Listing
January 2018

Update of systemic immunotherapy for advanced urothelial carcinoma.

Urol Oncol 2017 12 25;35(12):678-686. Epub 2017 Oct 25.

Dana Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.09.021DOI Listing
December 2017

Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.

Eur Urol 2018 02 28;73(2):153-155. Epub 2017 Sep 28.

Bladder Cancer Center, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838173077
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2017.09.012DOI Listing
February 2018